Trident Lifeline

Surat, India Founded: 2014 • Age: 12 yrs Listed
Manufacturer of liquid orals, topical preparations, capsule, and other drugs

About Trident Lifeline

Trident Lifeline is a publicly listed company based in Surat (India) founded in 2014. Manufacturer of liquid orals, topical preparations, capsule, and other drugs. The company has 74 employees. Trident Lifeline has completed 1 acquisition, including Tll Herbal. Its Indian entity Trident Lifeline Limited reported revenue of β‚Ή138 Cr. Trident Lifeline offers products and services including Pharmaceuticals and Nutraceuticals. Its focus areas include Traditional Pharmaceuticals and Diversified.

Company details

Trident Lifeline was established in 2014 in Surat, India, within the pharmaceutical sector. Operations focus on the production of liquid orals, topical preparations, capsules, and additional drug formulations. Manufacturing activities are centered in India, supporting domestic pharmaceutical needs. Leadership is provided by Managing Director Hardik Desai, with the company maintaining a domain at tridentlifeline.com for operational purposes.

  • Headquarters Surat, India
  • Employees 74
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website tridentlifeline.com
  • Social LinkedIn X Facebook Instagram
  • Legal Name Trident Lifeline Ltd.
Key Metrics
  • Market Cap
    ₹491 Cr

    TLL · BSE

  • Share Price
    ₹406.05

    -0.96% today

  • Revenue
    ₹129 Cr

    FY 2025-26 · +48.4% YoY

  • EBITDA
    ₹28.11 Cr

    Margin 21.8%

  • Net Profit
    ₹19.03 Cr

    FY 2025-26 · +62.2% YoY

  • P/E (TTM)
    21.1x

    P/B 4.2x

  • ROE
    23.4%

    ROCE 22.3%

  • Debt / Equity
    0.77

    Interest cover 24.1x

  • Employee Count
    74
  • Investments & Acquisitions

Products & Services of Trident Lifeline

Trident Lifeline offers a comprehensive portfolio of products and services, including Pharmaceuticals and Nutraceuticals.

Pharmaceuticals
Medicines

High-quality medicines are manufactured and marketed by Trident Lifeline, including tablets, capsules, and oral liquids, to address various healthcare requirements.

Nutraceuticals
Supplements

Nutritional supplements are formulated by Trident Lifeline to promote wellness, encompassing tablets, capsules, and sachets for supporting a healthy lifestyle.

Board of directors of Trident Lifeline Limited (Trident Lifeline)

Trident Lifeline Limited is the primary company behind Trident Lifeline. The board of Trident Lifeline Limited currently have 8 directors; the longest-serving is Hardik Jigishkumar Desai, appointed in 2022. 9 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Hardik Jigishkumar Desai
DIN 01358227
Director27 Jun 20224 yrs 4 moTrident Lifeline Limited
Shravan H Patel
DIN 08629141
Managing Director04 Jul 20224 yrs 4 moTrident Lifeline Limited
Mishal Shailesh Patel
DIN 10250091
Director22 Jul 20233 yrs 4 moTrident Lifeline Limited
Falguni Bhavesh Jariwala
DIN 10584711
Director27 Apr 20242 yrs 6 moTrident Lifeline Limited
Rupaben Chetan Jariwala
DIN 08543127
Whole-time director16 May 20242 yrs 6 moTrident Lifeline Limited
Ashish Anandsingh Bafna
DIN 01796556
Director01 Sep 20251 yr 2 moTrident Lifeline Limited
Smita Kiran Davda
DIN 11125469
Director13 Jun 20265 moTrident Lifeline Limited
Sachin Bhandari
DIN 11768182
Director13 Jun 20265 moTrident Lifeline Limited

People of Trident Lifeline

2 people are tracked at Trident Lifeline (2 in leadership); the tracked headcount is 74.

NameRoleGroup
Managing DirectorLeadership
Chief Executive OfficerLeadership
Premium access

Complete people profiles for Trident Lifeline

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Trident Lifeline

Trident Lifeline is a publicly listed company on the BSE with ticker symbol TLL in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date10 Oct 2022
  • Listed onBSE: 543616
  • Listed entityTrident Lifeline Ltd.
  • Exchange sectorHealth technology
  • ISININE0MKA01014
  • Share price₹409.00 (+8.2% on the day) · 2026-10-14
  • Market capitalisation₹451 Cr
  • Price to earnings22.8
  • EPS (diluted, trailing year)₹17.90
  • Volume (last session)20,400

Financials of Trident Lifeline

Exchange-reported figures of Trident Lifeline Limited, the listed company behind Trident Lifeline (BSE: TLL).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹129 Cr
+48.4% YoY
EBITDA
₹28.11 Cr
+87.4% YoY
Profit After Tax
₹19.03 Cr
+62.2% YoY
Net Worth
₹100 Cr
+55.8% YoY
Total Assets
₹181 Cr
+46.2% YoY
Total Debt
₹72.99 Cr
+35.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Income statement
Revenue12986.9644.6331.6921.77
Revenue growth+48.4%+94.9%+40.8%+45.6%-
EBITDA28.1115.008.236.262.71
EBITDA margin+21.8%+17.3%+18.4%+19.8%+12.5%
Profit before tax27.1913.608.696.582.98
Net profit19.0311.736.336.023.94
Net profit margin+14.8%+13.5%+14.2%+19.0%+18.1%
EPS (β‚Ή)16.3210.225.525.234.93
Balance sheet
Total assets18112472.4354.877.30
Net worth10064.4652.9045.644.78
Total debt72.9954.0318.417.692.46
Cash & bank4.222.466.6513.780.16
Net working capital84.5658.5837.3241.514.13
Cash flow
Cash from operations4.69(3.98)2.23(19.00)(0.21)
Cash from investing(36.61)(13.71)(20.36)(9.69)(0.45)
Cash from financing33.6813.5011.0142.280.80
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue47.0833.7249.9525.7131.3423.6134.0111.83
Revenue growth (YoY)+50.2%+42.8%+46.9%+117.3%+102.9%+79.5%--
Other income0.970.571.624.631.671.351.870.56
EBITDA11.328.5210.985.096.865.178.534.08
EBITDA margin+24.0%+25.3%+22.0%+19.8%+21.9%+21.9%+25.1%+34.5%
Depreciation1.561.621.232.460.911.462.740.61
Interest1.930.860.771.240.991.131.550.55
Profit before tax8.806.6110.606.026.633.936.113.48
Tax2.211.543.821.371.541.15(0.02)0.92
Net profit6.595.076.784.655.092.786.132.56
EPS (β‚Ή)5.694.275.763.724.272.666.152.42
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10267.8044.6531.6921.779.624.93
Revenue growth+50.3%+51.9%+40.9%+45.6%+126.3%+95.1%-
EBITDA24.3317.668.876.262.711.26(0.28)
EBITDA margin+23.9%+26.1%+19.9%+19.8%+12.5%+13.1%-5.7%
Profit before tax24.9817.899.796.572.980.87(1.09)
Net profit18.0913.047.036.013.940.65(0.82)
Net profit margin+17.8%+19.2%+15.7%+19.0%+18.1%+6.8%-16.6%
EPS (β‚Ή)15.5011.356.135.234.931.26(2.57)
Balance sheet
Total assets12480.6958.9449.087.304.113.52
Net worth99.0965.7352.6845.634.78(0.47)(3.00)
Total debt24.6014.896.203.382.464.536.46
Cash & bank4.072.116.0113.770.130.090.12
Net working capital75.5452.4938.6940.444.110.40(0.05)
Cash flow
Cash from operations7.931.970.90(16.60)(0.19)1.48(0.59)
Cash from investing(20.07)(7.88)(11.01)(5.56)(0.50)(0.56)(0.08)
Cash from financing14.102.012.3535.800.80(0.96)0.76
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue32.7326.8431.9723.6746.2618.8220.8516.51
Revenue growth (YoY)-29.3%+42.6%+53.3%+43.4%+195.4%+27.7%--
Other income0.930.531.640.891.640.541.610.54
Total expenses22.9819.6225.2317.3934.9513.8915.2712.37
EBITDA9.757.226.746.2811.314.935.584.14
EBITDA margin+29.8%+26.9%+21.1%+26.5%+24.4%+26.2%+26.8%+25.1%
Depreciation0.570.700.040.711.110.510.710.38
Interest1.320.490.380.540.740.330.460.35
Profit before tax8.796.567.965.9211.104.636.023.95
Tax2.211.542.291.912.691.151.660.92

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue47.0833.7249.9525.7131.3423.6134.0111.83
Revenue growth (YoY)+50.2%+42.8%+46.9%+117.3%+102.9%+79.5%--
Other income0.970.571.624.631.671.351.870.56
EBITDA11.328.5210.985.096.865.178.534.08
EBITDA margin+24.0%+25.3%+22.0%+19.8%+21.9%+21.9%+25.1%+34.5%
Depreciation1.561.621.232.460.911.462.740.61
Interest1.930.860.771.240.991.131.550.55
Profit before tax8.806.6110.606.026.633.936.113.48
Tax2.211.543.821.371.541.15(0.02)0.92
Net profit6.595.076.784.655.092.786.132.56
EPS (β‚Ή)5.694.275.763.724.272.666.152.42
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Revenue12986.9644.6331.6921.77
Revenue growth+48.4%+94.9%+40.8%+45.6%-
Other income9.278.232.081.160.60
Total expenses10171.9636.4025.4319.06
Employee cost0.0010.892.291.391.10
EBITDA28.1115.008.236.262.71
EBITDA margin+21.8%+17.3%+18.4%+19.8%+12.5%
Depreciation6.075.490.970.360.20
Interest4.124.140.650.480.13
Profit before tax27.1913.608.696.582.98
Tax7.883.122.750.56(0.96)
Net profit19.0311.736.336.023.94
Net profit margin+14.8%+13.5%+14.2%+19.0%+18.1%
EPS (β‚Ή)16.3210.225.525.234.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Equity & liabilities
Share capital11.9311.5011.5011.508.00
Reserves & surplus84.7452.9640.4134.14(3.22)
Shareholders' funds (net worth)10064.4652.9045.644.78
Minority interest7.495.191.051.470.00
Secured loans56.6541.1514.426.200.60
Unsecured loans16.3412.883.991.491.86
Total debt72.9954.0318.417.692.46
Total liabilities18112472.4354.877.30
Assets
Gross block78.3057.4023.034.332.23
Net block60.7043.8720.893.161.43
Capital work in progress17.541.604.034.830.00
Investments8.2710.723.773.340.00
Inventories36.4428.2412.587.173.71
Sundry debtors73.6527.6813.4412.094.97
Cash & bank balances4.222.466.6513.780.16
Loans & advances25.1831.9919.2916.171.83
Total current assets13990.3751.9649.2110.67
Total current liabilities54.9331.7914.647.706.54
Net working capital84.5658.5837.3241.514.13
Total assets18112472.4354.877.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Opening cash2.466.6513.780.180.01
Net cash from operating activities4.69(3.98)2.23(19.00)(0.21)
Net cash from investing activities(36.61)(13.71)(20.36)(9.69)(0.45)
Net cash from financing activities33.6813.5011.0142.280.80
Net change in cash1.76(4.19)(7.13)13.600.14
Closing cash4.222.466.6513.780.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Growth
Sales growth+48.4%+94.9%+40.8%+45.6%-
EBITDA growth+87.4%+82.3%+31.5%+131.0%-
PBT growth+100.1%+56.5%+32.1%+120.8%+9997.0%
Net income growth+62.2%+85.3%+5.2%+52.8%-
Revenue CAGR (3Y)+59.7%+58.7%---
EBITDA CAGR (3Y)+65.1%+76.9%---
Profitability & leverage
Net income margin+15.0%+12.1%+13.3%+19.0%+18.1%
Return on capital employed+22.3%+18.7%+15.0%+22.1%+29.7%
Return on net worth+23.4%+17.9%+12.1%+22.4%+49.4%
Debt / equity0.770.620.260.200.51
Long-term debt / equity0.430.380.170.100.30
Interest cover24.0943.538.958.145.18
Efficiency & per share
Fixed asset turnover1.902.163.269.669.76
Inventory turnover3.994.264.525.835.87
Debtors turnover2.554.233.503.724.38
EPS (β‚Ή)15.9610.225.525.234.93
Dividend per share (β‚Ή)0.000.000.000.000.00
Book value per share (β‚Ή)81.0256.0545.1439.695.97
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue32.7326.8431.9723.6746.2618.8220.8516.51
Revenue growth (YoY)-29.3%+42.6%+53.3%+43.4%+195.4%+27.7%--
Other income0.930.531.640.891.640.541.610.54
Total expenses22.9819.6225.2317.3934.9513.8915.2712.37
EBITDA9.757.226.746.2811.314.935.584.14
EBITDA margin+29.8%+26.9%+21.1%+26.5%+24.4%+26.2%+26.8%+25.1%
Depreciation0.570.700.040.711.110.510.710.38
Interest1.320.490.380.540.740.330.460.35
Profit before tax8.796.567.965.9211.104.636.023.95
Tax2.211.542.291.912.691.151.660.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10267.8044.6531.6921.779.624.93
Revenue growth+50.3%+51.9%+40.9%+45.6%+126.3%+95.1%-
Other income4.173.142.201.150.600.160.07
Total expenses77.5750.1435.7825.4319.068.365.21
Employee cost0.002.511.551.391.100.700.71
EBITDA24.3317.668.876.262.711.26(0.28)
EBITDA margin+23.9%+26.1%+19.9%+19.8%+12.5%+13.1%-5.7%
Depreciation1.861.530.770.360.200.140.12
Interest1.661.380.510.480.130.410.76
Profit before tax24.9817.899.796.572.980.87(1.09)
Tax6.894.852.750.56(0.96)0.22(0.28)
Net profit18.0913.047.036.013.940.65(0.82)
Net profit margin+17.8%+19.2%+15.7%+19.0%+18.1%+6.8%-16.6%
EPS (β‚Ή)15.5011.356.135.234.931.26(2.57)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.9311.5011.5011.508.005.003.10
Reserves & surplus83.4354.2341.1834.13(3.22)(5.47)(6.10)
Shareholders' funds (net worth)99.0965.7352.6845.634.78(0.47)(3.00)
Secured loans21.2013.026.202.730.600.000.00
Unsecured loans3.401.870.000.651.864.536.46
Total debt24.6014.896.203.382.464.536.46
Total liabilities12480.6958.9449.087.304.113.52
Assets
Gross block33.9118.269.554.272.231.771.22
Net block28.5914.807.623.111.431.180.77
Capital work in progress0.000.544.030.230.000.000.00
Investments19.7412.494.404.040.050.000.00
Inventories23.2216.5711.067.173.715.270.94
Sundry debtors49.3420.4013.7612.154.970.641.31
Cash & bank balances4.072.116.0113.770.130.090.12
Loans & advances33.4130.0522.1514.771.831.740.45
Total current assets11069.1352.9847.8610.647.742.82
Total current liabilities34.5016.6414.297.426.537.342.87
Net working capital75.5452.4938.6940.444.110.40(0.05)
Total assets12480.6958.9449.087.304.113.52
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2.116.0113.770.130.010.120.04
Net cash from operating activities7.931.970.90(16.60)(0.19)1.48(0.59)
Net cash from investing activities(20.07)(7.88)(11.01)(5.56)(0.50)(0.56)(0.08)
Net cash from financing activities14.102.012.3535.800.80(0.96)0.76
Net change in cash1.96(3.90)(7.76)13.640.11(0.03)0.08
Closing cash4.072.116.0113.770.130.090.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+50.3%+51.9%+40.9%+45.6%+126.3%+95.1%-
EBITDA growth+37.8%+99.1%+41.7%+131.0%+115.1%+550.0%-
PBT growth+39.6%+82.7%+49.0%+120.5%+242.5%+9998.0%+9997.0%
Net income growth+38.7%+85.5%+17.0%+52.5%+506.2%+179.3%-
Revenue CAGR (3Y)+47.6%+46.0%+66.8%+85.9%---
EBITDA CAGR (3Y)+57.3%+86.8%+91.7%----
Profitability & leverage
Net income margin+17.8%+19.2%+15.8%+19.0%+18.1%+6.8%-16.4%
Return on capital employed+26.1%+27.6%+19.1%+23.7%+31.0%+19.2%0.0%
Return on net worth+22.0%+22.0%+14.3%+22.4%+60.8%+63.0%0.0%
Debt / equity0.240.180.100.121.620.000.00
Long-term debt / equity0.080.080.040.041.360.000.00
Interest cover7.478.566.308.145.1836.61-190.00
Efficiency & per share
Fixed asset turnover3.914.886.469.7510.896.434.04
Inventory turnover5.124.914.905.834.853.105.24
Debtors turnover2.923.973.453.707.769.873.76
EPS (β‚Ή)15.1611.356.135.234.931.26(2.57)
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)79.9157.1645.8139.685.97(0.94)(9.69)

Investments & Acquisitions by Trident Lifeline

Trident Lifeline has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tll Herbal.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Anti-freeze preparations and chemical-related products are manufactured by Tll Herbal.
tllherbal.comSurat, India2019Jul 2023$572,613
Premium access

Complete acquisition details for Trident Lifeline

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Trident Lifeline

3 dated milestones of Trident Lifeline across 9 years, from founding to its latest funding, stage changes and deals.

  1. Founded Trident Lifeline is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Tll Herbal.

Web traffic of Trident Lifeline

The website of Trident Lifeline (tridentlifeline.com) receives about 1K visits a month.

  • Monthly visits
    1K

    ▼ 4% vs previous month

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Trident Lifeline (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Trident Lifeline

Premium access

Complete news archive for Trident Lifeline

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Trident Lifeline

Trident Lifeline was founded in 2014.

Trident Lifeline is headquartered in Surat, India. It is registered at Surat, Gujarat, India.

Trident Lifeline has 74 employees.

The primary company behind Trident Lifeline, Trident Lifeline Limited, reported revenue of β‚Ή138 Cr for FY 2026, up 48% year on year.

Trident Lifeline was established in 2014 in Surat, India, within the pharmaceutical sector. Operations focus on the production of liquid orals, topical preparations, capsules, and additional drug formulations. Manufacturing activities are centered in India, supporting domestic pharmaceutical needs. Leadership is provided by Managing Director Hardik Desai, with the company maintaining a domain at tridentlifeline.com for operational purposes.

Trident Lifeline offers Pharmaceuticals and Nutraceuticals.

Yes, Trident Lifeline is publicly traded on BSE under the ticker symbol TLL.

Trident Lifeline has made 1 acquisition, including Tll Herbal.

Trident Lifeline operates through Trident Lifeline Limited.

The legal entities of Trident Lifeline currently have 9 directors, including Hardik Jigishkumar Desai, Shravan H Patel, Nikita Sharma and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available